News Details

Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment. Long term indicators fully support a continuation of the trend. Realtime quote and/or trades are not sourced from all markets.

On corrections up, there will be some resistance from the lines at $0.432 and $0.558. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Friday, February 03, 2023, and so far it has fallen -39.02%. Further fall is indicated until a new bottom pivot has been found. Volume fell on the last day without any changes to the price.

These investments are speculative, involve substantial risks , and are not FDIC or SIPC insured. Alternative Assets purchased on the Public platform are not held in an Open to the Public Investing brokerage account and are self-custodied by the purchaser. The issuers of these securities may be an affiliate of Public, and Public may earn fees when you purchase or sell Alternative Assets.

BTIG Sticks to Its Buy Rating for Verastem (VSTM)

Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. 11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among the company’s employees.

Brokerage services for US-listed, registered securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”).

Is It Time to Buy? VSTM Shares are up today.

Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.

Live educational sessions using site features to explore today’s markets. CUP AND HANDLE FORMING NEW PT 6.50+Price above 200 EMA. There may be delays, omissions, or inaccuracies in the Information. As an investor, you want to buy stocks with the highest probability of success.

Industry

U.S. Treasuries (“T-Bill“) investing services on the Public Platform are offered by Jiko Securities, Inc. (“JSI”), a registered broker-dealer and member of FINRA & SIPC. See JSI’s FINRA BrokerCheck and Form CRS for further information. When you enable T-Bill investing on the Public platform, you open a separate brokerage account with JSI (the “Treasury Account“). You can find your newly purchased Verastem stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, and alternative assets.

According to analysts’ consensus price target of $4.25, Verastem has a forecasted upside of 849.1% from its current price of $0.45. The company’s average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings. The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current four trading questions you should ask your forex broker direction. VSTM climbed in early trading after boosting the size of its deal. The company’s stock opened at $11 a share on the Nasdaq, up from its initial public offering price of $10… The Verastem stock holds several negative signals and despite the positive trend, we believe Verastem will perform weakly in the next couple of days or weeks.

(Real Time Quote from BATS)

Investments in T-bills involve a variety of risks, including credit risk, interest rate risk, and liquidity risk. As a general rule, the price of a T-bills moves inversely to changes in interest rates. See Jiko U.S. Treasuries Risk Disclosures for further details.

Therefore, we hold a negative evaluation of this stock. On the downside, the stock finds support just below today’s level from accumulated volume at $0.391 and $0.386. There is a natural risk involved https://day-trading.info/ when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Verastem finds support just below today’s level at $0.391.

Some negative signals were issued as well, and these may have some influence on the near short-term development. The Verastem stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.

• The high in the last 52 weeks of Verastem stock was 2.13.
• To see all exchange delays and terms of use please see Barchart’s disclaimer.
• If the flag holds, it looks like it could hit around $4.60.
• ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
• Only 8 people have added Verastem to their MarketBeat watchlist in the last 30 days.

Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. A handful of earnings surprises are likely to keep investors busy early Thursday. 12.65% during the next 3 months and, with a 90% probability hold a price between $0.445 and $0.84 at the end of this 3-month period. The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries.

Barchart Technical Opinion

That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

Market cap is the total market value of a publicly traded company’s outstanding shares. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. In the past three months, Verastem insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $443.00 in company stock. Verastem has only been the subject of 2 research reports in the past 90 days. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Verastem has been upgraded to a Zacks Rank #1 , reflecting growing optimism about the company’s earnings prospects.

This does not cause any direct divergence but may be an early warning and a possible “turning point”. Agenus, Dynavax Technologies, and Verastem Oncology could all be outstanding picks for risk-tolerant investors. George Budwell Normally, companies with share prices lower than $5 — commonly called penny stocks — wouldn’t even be worth a glance. According to 12 analysts, the average rating for VSTM stock is “Buy.” The 12-month stock price forecast is $4.16, which is an increase of 830.65% from the latest price. 3 Monster Growth Stocks That Could Reach New Highs Let’s talk about growth stocks. These are stocks that have shown strong and sustained share price appreciation, sometimes…

This suggests a possible upside of 888.4% from the stock’s current price. View analysts price targets for VSTM or view top-rated stocks among Wall Street analysts. 5 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Verastem in the last twelve months. The consensus among Wall Street equities research analysts is that investors should “buy” VSTM shares. Verastem Oncology is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer.

If you had invested in Verastem stock at $11.09, your return over the last 11 years would have been -96.12%, for an annualized return of -25.58% . Overall, this stock passed 12/33 due dilligence checks and has average fundamentals, according to our automated analysis. Wainwright H.C. Wainwright analyst Sean Lee lowered the firm’s price target on Verastem to $3 from $5 and keeps…

Verastem reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.099. Following the earnings report the stock price went same N/A. Verastem released its earnings results on Mar 14, 2023. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.099 by $0.019. Verastem reports interim data from Part A of the ongoing RAMP 201 Phase 2 study Verastem Oncology announces positive interim data from Part A of the ongoing RAMP 201 international registration-directed Phase 2… Verastem reports Q4 EPS , consensus Verastem Oncology ended the fourth quarter of 2022 with cash, cash equivalents and investments of $87.9M.